Jim Cramer Notes “Merck’s Cancer Dominance Has Been Challenged of Late By JNJ”

Jim Cramer Notes “Merck’s Cancer Dominance Has Been Challenged of Late By JNJ” Syeda Seirut Javed Mon, June 1, 2026 at 7:42 PM GMT+2 2 min read MRK Merck & Co. , Inc. (NYSE: MRK ) was among the stocks Jim Cramer was focused on, as he discussed Mad Money’s latest game plan for the week .

It was one of the stocks mentioned in Cramer’s game plan, as he remarked: Now Merck… Monday evening, very odd… the actual 6:00 PM, hosts a meeting to review its cancer portfolio after the 2026 American Society of Clinical Oncology Conference. That’s the most important cancer confab of the year. Merck’s cancer dominance has been challenged of late by JNJ.

Let’s see what Merck has to say. Photo by Adam Nowakowski on Unsplash Merck & Co. , Inc.

(NYSE:MRK) is a healthcare company that provides a wide range of human and veterinary pharmaceuticals, vaccines, and health solutions. A caller asked about the stock during the May 1 episode, and Cramer responded: Okay, I thought Merck got, you know what, Merck reported a really good quarter, and it just happened on a day when people didn’t like pharma, and they didn’t like healthcare. And Rob Davis did a good job.

The stock’s starting to come back. It was up $3 today. I think it can manage its way, all the way back to $120.

I think you do good homework. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years   Disclosure: None. Follow Insider Monkey on Google News .